What to Make of the GLP-1 Coverage and Cost Landscape
How payers are handling the rise of GLP-1s? Cost and clinical transparency can support whatever strategy a plan takes.
How payers are handling the rise of GLP-1s? Cost and clinical transparency can support whatever strategy a plan takes.
Up to 10 competing products for Humira are on the way in 2023. What should health plans and plan sponsors be following as the biosimilars landscape takes shape?
Some lesser-known facts about this chronic condition underscore the importance of medication adherence, and the positive impact RxSS can have on members with diabetes.